Study immune cell changes with Orencia in rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies how Orencia (abatacept) affects your immune system’s T and B cells in people with rheumatoid arthritis. It may help researchers better understand who responds to Orencia and what immune changes happen over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) with diagnosed rheumatoid arthritis (RA)
- You are currently taking methotrexate (MTX), with or without other non-steroid RA medicines, at a stable dose
- You have not taken Orencia (abatacept) or rituximab before (and you also stopped certain other RA medicines long enough ago)
- Your RA treatment plan and recent disease activity match one of the study groups (starting Orencia vs staying on stable treatment vs healthy controls)
- You are not taking high-dose prednisone (over 10 mg by mouth each day), and certain steroid shots must not have been used recently
- If you could become pregnant, you must use effective birth control during the whole study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.